Fredric Price of Chiasma was CEO of Omrix until 2008 when they sold to the Ethicon division of Johnson & Johnson for $438 million. One of Omrix’s main innovations involves using blood platelets to manufacture bandages that instantly close a wound using the inherent properties of the platelets. As they continue to develop the Fibrin Pad, a large pad which can stop the bleeding of an internal gash several square inches, they are moving in the direction of preserving many lives, especially out on the battlefield.
Mr. Gethin described how careful you need to be when you are making a product designed to be surgically inserted into human beings, and there is a high level of strict management procedures necessary to comply with. Israelis are much better at innovating than at managing the growth of their innovations, so Johnson & Johnson has brought in several foreigners to properly manage the operation.
We took a tour of the plant and I was impressed to see how they have 2 sets of machines that each go from beginning to end of their manufacturing process. They set up this system to enable an upgrade of machinery without having to pause the plant. Additionally, each section of each line is separated from every other section to decrease the potential for contamination.
I guess they weren’t worried about us sneezing or touching things (photo credit: Prof. Bachenheimer)
The outside of the building (photo credit: Julie)